Combination drug therapy for lung cancer with brain spread
Treatments studied
Part of Brain & nervous system, Cancer, Lungs & breathing clinical trials.
This trial tests a combination of two drugs, sacituzumab govitecan and bevacizumab, for people with a specific type of lung cancer (non-squamous) that has spread to the brain. It aims to see if this treatment can shrink brain tumors and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have metastatic non-squamous non-small cell lung cancer that has spread to your brain.
- You have at least one untreated brain tumor that is 5 mm or larger and not in a sensitive area of the brain.
- You have previously tried immunotherapy, chemotherapy, or targeted therapy and it stopped working.
- You are generally in good health (able to do daily activities without much help) with a life expectancy of at least 3 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing a combination of a targeted drug (Sacituzumab Govitecan) and radiation to the head for people with HER2-negative breast cancer that has spread to the brain. The goal is to see if this combination can help shrink brain tumors and improve outcomes.
This trial tests a combination of two drugs (Sac-TMT and bevacizumab) for people with a specific type of non-small cell lung cancer that has spread to the brain and has stopped responding to a certain targeted therapy. The goal is to see if this combination can shrink brain tumors and improve outcomes.
This trial tests a combination of two drugs, Sacituzumab Govitecan and Bevacizumab, for people with advanced triple-negative breast cancer that has already been treated. The goal is to see if the combination works better than standard treatments.
This trial tests a combination of two drugs, Sac-TMT and bevacizumab, as a second treatment option for people with advanced non-squamous non-small cell lung cancer whose cancer has gotten worse after initial chemotherapy and immunotherapy. The goal is to see if this combination can help shrink tumors or slow the disease.
This trial tests a combination of two drugs, sacituzumab tirumotecan and toripalimab, given before surgery to shrink early-stage NSCLC (stage II to IIIB) that can be removed. The goal is to see if this approach improves outcomes compared to standard treatment.
This trial tests sacituzumab govitecan (an antibody-drug medicine) with or without pembrolizumab (an immune-system therapy) in people with metastatic triple-negative breast cancer. It may help by shrinking tumors and improving immune control, especially for patients with specific tumor marker results.
Hear when a new NSCLC Stage IV trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.